Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-5 (of 5 Records) |
Query Trace: Lyde F[original query] |
---|
Rotavirus G9P[4] in 3 countries in Latin America, 2009-2010
Quaye O , McDonald S , Esona MD , Lyde FC , Mijatovic-Rustempasic S , Roy S , Banegas DJ , Quinonez YM , Chinchilla BL , Santiago FG , Lozano HG , Rey-Benito G , de Oliveira LH , Gentsch JR , Bowen MD . Emerg Infect Dis 2013 19 (8) 1332-3 Group A rotaviruses are the most common viral cause of acute gastroenteritis in young children. The most frequently detected group A rotavirus genotype combinations include G1P[8], G2P[4], G3P[8], G4P[8], and G9P[8]. The G9 genotype has been associated with multiple P types, including P[8], P[6], and P[4], although genotype G9P[8] is predominant (1). | In Latin America, a large number of unusual G-P combinations have been reported, and among these is the rare G9P[4] genotype, which was identified in Brazil in the 1990s (2), and later reported infrequently elsewhere in Latin America (3). In 2010, cases of group A rotavirus gastroenteritis associated with genotype G9P[4] were reported in Mexico (4). Increases in the incidence of group A rotavirus gastroenteritis were reported in 2010 in Mexico and Guatemala and in 2009 in Honduras (http://new.paho.org/hq/dmdocuments/2010/Epi_Alerts_2010_mar_5_rotavirus.pdf). | In response to these reports of increased group A rotavirus disease, fecal samples collected in Chiapas State, Mexico (in 2010, 30% of the cases in Mexico were from Chiapas), Guatemala, and Honduras in 2009–2010 that were positive by enzyme immunoassay were sent to the US Centers for Disease Control and Prevention (Atlanta, GA, USA) for characterization. Viral protein 4 (VP4) (P) and VP7 (G) genotyping, nucleotide sequencing, and genotype identification were performed by using consensus and genotype-specific oligonucleotide primers (5), and sequences were subjected to phylogenetic analyses. VP6 and nonstructural protein 4 (NSP4) genes of selected samples were also sequenced. |
Comparison of 2 assays for diagnosing rotavirus and evaluating vaccine effectiveness in children with gastroenteritis
Tate JE , Mijatovic-Rustempasic S , Tam KI , Lyde FC , Payne DC , Szilagyi P , Edwards K , Staat MA , Weinberg GA , Hall CB , Chappell J , McNeal M , Gentsch JR , Bowen MD , Parashar UD . Emerg Infect Dis 2013 19 (8) 1245-52 We compared rotavirus detection rates in children with acute gastroenteritis (AGE) and in healthy controls using enzyme immunoassays (EIAs) and semiquantitative real-time reverse transcription PCR (qRT-PCR). We calculated rotavirus vaccine effectiveness using different laboratory-based case definitions to determine which best identified the proportion of disease that was vaccine preventable. Of 648 AGE patients, 158 (24%) were EIA positive, and 157 were also qRT-PCR positive. An additional 65 (10%) were qRT-PCR positive but EIA negative. Of 500 healthy controls, 1 was EIA positive and 24 (5%) were qRT-PCR positive. Rotavirus vaccine was highly effective (84% [95% CI 71%-91%]) in EIA-positive children but offered no significant protection (14% [95% CI -105% to 64%]) in EIA-negative children for whom virus was detected by qRT-PCR alone. Children with rotavirus detected by qRT-PCR but not by EIA were not protected by vaccination, suggesting that rotavirus detected by qRT-PCR alone might not be causally associated with AGE in all patients. |
Comparison of Premier Rotaclone, ProSpecT, and RIDASCREEN rotavirus enzyme immunoassay kits for detection of rotavirus antigen in stool specimens
Gautam R , Lyde F , Esona MD , Quaye O , Bowen MD . J Clin Virol 2013 58 (1) 292-4 BACKGROUND: Rotaviruses are the major cause of severe dehydrating diarrhea in children throughout the world. Enzyme immunoassays (EIAs) have been the standard method for detection of rotavirus in stool specimens since the 1980s. The World Health Organization (WHO) Rotavirus Surveillance Network has proposed including three EIA kits in the WHO-GSM (Global Management System/Systeme Mondial de Gestion) catalog for easy procurement of EIA kits by participating rotavirus surveillance network laboratories. OBJECTIVES: In this study, we conducted a comparative analysis of 3 commercially available enzyme immunoassay kits: Premier Rotaclone(R) (Meridian Bioscience, Inc.), ProSpecT (Oxoid, Ltd.) and RIDASCREEN(R) (R-biopharm AG) for rotavirus diagnostics. STUDY DESIGN: Using reverse-transcriptase-PCR (RT-PCR) as the gold standard, the 3 EIA kits were evaluated by testing a stool panel consisting of 56 rotavirus-positive and 54 rotavirus negative samples. RESULTS: The sensitivities of the Premier Rotaclone(R), ProSpecT and RIDASCREEN(R) kits were 76.8%, 75% and 82.1%, respectively, but did not differ significantly. The specificity of all the 3 kits was 100%. The use of RT-PCR as a gold standard lowered the observed sensitivity of all 3 EIA kits but helps to reduce equivocal results that can be seen when another EIA or other non-molecular methods are used as the reference assay in comparison studies. CONCLUSION: Our study found that all three kits are suitable for use by rotavirus surveillance programs. |
Symptomatic infection and detection of vaccine and vaccine-reassortant rotavirus strains in 5 children: a case series
Boom JA , Sahni LC , Payne DC , Gautam R , Lyde F , Mijatovic-Rustempasic S , Bowen MD , Tate JE , Rench MA , Gentsch JR , Parashar UD , Baker CJ . J Infect Dis 2012 206 (8) 1275-9 Vaccine or vaccine-reassortant rotavirus strains were detected in fecal specimens from 5 of 106 (4.7%) immunocompetent children who required treatment for rotavirus gastroenteritis at a large pediatric hospital in Texas in 2009-2010. Four strains were related to pentavalent rotavirus vaccine, whereas one was related to monovalent rotavirus vaccine. The contribution of these strains to each patient's illness was unclear given that 2 patients had prominent respiratory symptoms and 2 were concurrently infected with another pathogen (group F adenovirus and norovirus). Continued monitoring is necessary to assess the role of vaccine strains and vaccine-reassortant strains in pediatric rotavirus infections. |
Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG
Semenova VA , Schiffer J , Steward-Clark E , Soroka S , Schmidt DS , Brawner MM , Lyde F , Thompson R , Brown N , Foster L , Fox S , Patel N , Freeman AE , Quinn CP . J Immunol Methods 2012 376 97-107 Accurate, reliable and standardized quantification of anti-protective antigen (PA) IgG antibody levels is essential for comparative analyses of anti-toxin immune responses in anthrax cases, recipients of PA-based anthrax vaccines and for evaluation of anti-PA based immunotherapies. We have previously reported the early performance characteristics and application of a quantitative anti-PA IgG enzyme linked immunosorbent assay. The principal application of this assay was in a Phase 4 human clinical trial of anthrax vaccine adsorbed (AVA, BioThrax), the central component of the CDC Anthrax Vaccine Research Program (AVRP) and in humans following bioterrorism associated Bacillus anthracis infection (Quinn et al., 2002; Quinn et al., 2004; Marano et al., 2008). The objective of the AVRP was to determine the feasibility of reducing the number of priming series and booster doses of the licensed Anthrax Vaccine Adsorbed (AVA) (BioThrax(R); Emergent BioSolutions, Lansing, MI) and changing the route of administration from subcutaneous (SC) to intramuscular (IM) (Marano et al., 2008). In this paper we report the validation and long term performance characteristics of the assay during its six year application in the AVRP (2002-2008). The critical features are 1) extensive validation of the assay using two standard reference sera; 2) long term stability and 3) consistency of the data for quantitative analysis of human long term anti-PA IgG responses. The reportable value (RV) of the assay was expressed as anti-PA IgG concentration (mcg/ml). Accuracy of the assay was high with a percent error (%ER) range of 1.6-11.4%. Overall intra-operator and intermediate precision were high with Coefficients of Variation (%CVs) of 2.5-15.4% and 6.3-13.2%, respectively. The assay demonstrated excellent dilutional linearity for human sera using log(10) transformed data with the slope=0.95 to 0.99, intercept=0.02 to 0.06 and r(2)=0.980-0.987. The assay was robust, tolerating changes in serum incubation temperatures from 35 to 39 degrees C, serum incubation times from 55 to 65min and changes in key reagents. The long-term assay stability over 6years using consecutive reference sera AVR414 and AVR801 demonstrated sustained high accuracy and precision for the assay, confirming its suitability for long term studies of PA protein-based anthrax vaccines. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure